Trendthema: Spätabnabeln in der Geburtshilfe

Verzögerte Nabelschnurdurchtrennung: Bei wem, wann und wie?
Dr. med. Robert Armbrust, Seiten 6-8

  1. Garofalo M,Haim A. Early Versus Delayed Cord Clamping Term and Preterm Births. A Review. J Obstet Gynaecol Can (2012) 34:525-531
  2. Hutton EK, Hassan ES. Late versus early clamping of the umbilical cord in full-term neonates. Systematic review and meta-analysis of controlledtrials. JAMA (2007) 297:1241-52
  3. Mathew JL. Timing of umbilical cord clamping in term and pretermdeliveries and infant and maternal outcomes: A systematic review of randomized controlled trials. Indian Pediatr (2011) 48:123-9
  4. McDonald SJ, Middleton P. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Review. The Cochrane Library (2009) Issue 1
  5. Rabe H, Reynolds G, Diaz-Rossello J. Early versus delayed umbilical cordclamping in preterm infants. Cochrane Database Syst Rev (2004) 4:CD003248
  6. Andersson O, Hellstrom-Westas L, Andersson D, Domellof M. Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iro status at 4 months: A randomised controlled trial. BMJ (2011) 343:d7157
  7. Rabe H, Reynolds G, Diaz-Rossello J. A systematic review and meta-analysis of a brief delay in clamping the umbilical cord of preterm infants. Neonatology (2008) 93:138-44
  8. Farrar D, Airey R, Law GR, Tuffnell D, Cattle B, Duley L. Measuring placental transfusion for term births: weighing babies with cord intact BJOG (2011) 118:70-5
  9. Aladangady N, McHugh S, Aitchison TC, Wardrop CA, Holland BM.Infants’ blood volume in a controlled trial of placental transfusion at preterm delivery. Pediatrics (2006) 117:93-8
  10. Kleinberg F, Dong L, Phibbs RH. Cesarean section prevents placenta-to-infant transfusion despite delayed cord clamping. Am J Obstet Gynecol (1975) 121:66-70
  11. Ogata ES, Kitterman JA, Kleinberg F, Dong L, Willis M, Mates J et al. The effect of time of cord clamping and maternal blood pressure on placental transfusion with cesarean section. Am J Obstet Gynecol (1977) 128:197-200
  12. McDonnell M, Henderson-Smart DJ. Delayed umbilical cordclamping in preterm infants: A feasibility study. J Paediatr Child Health (1997) 33:308-10
  13. Mercer JS, Vohr BR, Erickson-Owens DA, Padbury JF, Oh W. 7-monthdevelopmental outcomes of very low birth weight infants enrolled in arandomized controlled trial of delayed versus immediate cord clamping.J Perinatol (2010)30:11-6
  14. Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W.Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: A randomized, controlledtrial. Pediatrics (2006) 117:1235-42

50 Jahre Gonadotropintherapie

Von der Grundlagenforschung bis zur klinischen Reife
Prof. Dr. med. Meinert Breckwoldt, Seiten 10-14

  1. Aschheim S.Zondek B. Das Hormon des Hypophysenvorderlappens. Klin. Wochenschrift (1928) 7;831-835
  2. Smith PE. Experimental ablation of the hypophysis in the frog embryo. Science (1916) 44; 280-282
  3. Fevold HL, Hisaw FL, Leonard L. The gonad stimulating and the luteinizing hormones of the anterior lobe of the hypophysis. Am J Physiol (1931) 97, 291-301
  4. Allen BM. Experments in the transplantation of the hypophysis of adult rana pipiens to tadpoles. Science (1920) 52; 274-276
  5. Aschheim S. Zondek B. Die Schwangerschaftsdiagnose aus dem Harn durch Nachweis des Hypophysenvorderlappenhormons. Klin. Wochenschrift (1928) 7; 1404-1411
  6. Philipp E. Die Bildungsstätten des Hypophysenvorderlappenhormons in der Gravidität. Zentrbl. Gynäkol (1930) 54; 1858-1866
  7. Cole HH, Hart GH. The potency of blood serum of mares in pregnancy in effecting the sexual maturity of the immature rat. Am J Physiol (1930) 93; 57-68
  8. Staemmler HJ. Die gestörte Regelung der Ovarialfunktion. Springer (1964) Berlin Göttingen Heidelberg
  9. Östergaard E. Antigonadotrophic substances under treatment with gonadotrophic hormones. E Munksgaard (1942) Copenhagen
  10. Breckwoldt M, Czygan PJ. Erfahrungen mit dem Ascorbinsäuretest nach Parlow. Geburtsh. Gynäkol. (1967) 167, 329-334
  11. Gemzell C. Induction of ovulation with human pituitary gonadotrophins. Fertil Steril (1962) 13; 153-160
  12. Bettendorf GM, Apostolakis K, Voigt D. Darstellung von Gonadotropinen aus menschlichen Hypophysen. Acta endocrinol. (1962) 41; 1-13
  13. Bettendorf G, Breckwoldt M, Knörr K, Stegner HE. Gravidität nach Hypophysektomie und Behandlung mit hypophysärem Humangonadotropin. Case report. Dtsch Med Wochenschr (1964) 89 (41); 1952-1957
  14. Bettendorf G. Gonadotrophins in human pituitaries. Acta endocrinol (1965) Suppl 101; 7-8
  15. Breckwoldt M, Bettendorf G, Wirkungen des hypophysären Human Gonadotropins bei der hypogonadotropen Ovarialinsuffizienz. Fortschr. Geburtsh Gynäk (1965) 21; 31-37
  16. Breckwoldt M, Czygan PJ, Bettendorf G. Extraction of LH preparation from human pituitaries. Acta endocrinol (1967) Suppl 119; 134
  17. Breckwoldt M, Bettendorf G, Garcia C. Induction of ovulations in amenorrhoic and hypophysectomized rhesus monkeys with various human gonadotropins. Fertil Steril (1971) 22; 451-456
  18. Lunenfeld B, Menzi A, Volet B. Clinical effects of human postmenopausal gonadotropins. I. Int Congr Endocrinology (1960) Copenhagen; Advance abstracts of short communications, Periodica Copenhagen
  19. Lunenfeld B, Insler V, Glezerman M. Diagnosis and treatment of functional infertility. Grosse Verlag (1978) Berlin
  20. Insler V, Melmed H, Eichenbrenner D, Serr M, Lunenfeld B. The cervical score. A simple semiquantitative method for monitoring of menstrual cycle. Int J Gynecol Obstet (1972) 10; 223-228
  21. Reichert LE. Preparation of purified bovine luteinizing hormone. Endocrinology (1962) 71; 729-733
  22. Midgley AR, Jaffe RB. Regulation of human gonadotropins. X Episodic fluctuations of LH during the menstrual cycle. J Clin Endocrinol Metab (1971) 33; 962-969
  23. Knobil E. On the control of gonadotrophin secretion in the rhesus monkey. Rec Progr Horm Res (1974) 30; 1-35
  24. Wildt I, Marshall G, Knobil E. Induction of ovarian function in sexually immature rhesus monkey by pulsatile administration of GnRH. Science (1980) 207; 1373-1379

Newsletter DGRM e.V. Haut & Sex

Dermatologische Krankheitsbilderhemmen das sexuelle Leben
Seiten 28-29

  1. Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. Br J Dermatol (2011) 165: 865-873
  2. Chung SD, Keller JJ, Chu TW, Lin HC. Psoriasis and the risk of erectile dysfunction. A population-based case-control study. J Sex Med (2012) 9: 130-135
  3. Chung SD, Keller JJ, Lin HC. Association of erectile dysfunction with atopic dermatitis. A population-based case-control study. J Sex Med (2012) 9: 679-85
  4. Ermertcan AT, Gencoglan G, Temeltas G, Horasan GD, Deveci A, Ozturk F. Sexual dysfunction in female patients with neurodermatitis. J Androl (2011) 32: 165-169
  5. Goulding JM, Price CL, Defty CL, Hulangamuwa CS, Bader E, Ahmed I. Erectile dysfunction in patients with psoriasis. increased prevalence, an unmet need and a chance to intervene. Br J Dermatol (2011) 164: 103-109
  6. Gupta MA, Gupta AK. Psoriasis and sex. a study of moderately to severely affected patients. Int J Dermatol (1997) 36: 259-262
  7. Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol (2012) 67: 422-428
  8. Kurizky PS, da Mota LMH. Sexual dysfunction in patients with psoriasis and psoriatic arthritis. A systematic review. Rev Bras Rheumatol (2012) 52: 938-948
  9. Magin P, Heading G, Adams J, Pond D. Sex and the skin. A qualitative study of patients with acne, psoriasis and atopic eczema. Psychol Health Med (2010) 15: 454-462
  10. Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof PC, van Rossum MM. Quality of life and sexual health in patients withgenital psoriasis. Br J Dermatol (2011) 164: 1247-1255
  11. Mojon-Azzi SM, Potnik W, Mojon DS. Opinions of dating agents about strabismic subjectsability to find a partner. Br J Ophthalmol (2011) 92: 765-769
  12. Niemeier V, Winckelesser T, Gieler U. Hautkrankheit und Sexualität. Hautarzt (1997) 48: 629-633
  13. Ramsay B, O’Reagan M. A survey of the social and psychological effects ofpsoriasis. Br J Dermatol (1988) 118: 195-201
  14. Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol (2013) 14: 1-7
  15. Van Dorssen IE, Boom BW, Hengeveld MW. Experience of sexuality in patients with psoriasis and constitutional eczema. Ned Tijdschr Geneeskd (2011) 136: 2175-2178

Hormonale Kontrazeption – Blutungsstörungen (Teil 1): Definition, methodenunabhängige Ursachen und Pathophysiologie

Gemeinsame Stellungnahme der DGGEF e.V. und des BVF e.V.
(Prof. Dr. med. Dr. med. h.c. Thomas Rabefederführend) und des Arbeitskreises
„Blutungsstörungen bei der Frau“
Seiten 30-37

  1. von Mackensen S. Quality of life in womenwith bleeding disorders. Haemophilia Special Issue. Women and Inherited Bleeding Disorders (2011) 17,2222Supplement s1, 33–37, DOI: 10.1111/j.1365-2516.2011.02563.x
  2. Royal College of General Practitioners. Oralcontraception and health. An interim report from theoral contraception study of the Royal College ofGeneral Practitioners;(1974) Pitnam, New York
  3. Lohr PA, Creinin MD. Oral contraceptives and breakthroughbleeding. Whatpatients need to know. JFamily Practice (2006) 55 (10);1-11
  4. Belsey EM, Machin D, d’Arcangues C. The analysisof vaginal bleeding patterns induced by fertilityregulating methods. World Health Organization. Special programme of research. Developmentand research training in human reproduction.Contraception (1986) 34:253–260
  5. Thorneycroft IH. Cycle control with oral contraceptives. A review of the literature. Am J Obstet Gynecol (1999) 180:S280-S287
  6. Belsey EM, Machin D, d’Arcangues C. The analysisof vaginal bleeding patterns induced by fertilityregulating methods. Contraception (1986) 34: 253-260
  7. Belsey EM, Machin D, d’Arcangues C. The analysisof vaginal bleeding patterns induced by fertilityregulatingmethods. Contraception (1986) 34;253-60
  8. D’Arcangues C, Odlind V, Fraser IS. Dysfunctional uterine bleeding induced by exogenous hormones.In: Alexander NJ, d’Arcangues C. eds. Steroid hormonesand uterine bleeding. Washington: AmericanAssociation for the Advancement of Science (1992) 81-105
  9. Fraser IS. Bleeding arising from the use of exogenoussteroids. In: Smith SK, ed. Dysfunctional uterinebleeding. Baillieres Clin Obstet Gynaecol (1999) 13; 203-222
  10. Rodriguez G, Faundes-Latham A, Atkinson L. Anapproach to the analysis of menstrual patterns inthe clinical evaluation of contraceptives. Stud FamPlan (1976) 7; 42-51
  11. Woolcock JG, Critchley HOD, Malcolm MG, BroderMS, Fraser IS. Review of the confusion in currentand historical terminology and definitions for disturbancesof menstrual bleeding. Fertil Steril (2008) 90; 2269-2280
  12. Mishell DR. Jr, Guillebaud J, Westhoff C, NelsonAL, Kaunitz AM, Trussell J, Davis AJ. Recommendationsfor standardization of data collection andanalysis of bleeding in combined hormone contraceptivetrials. Contraception (2007) 75;11-15
  13. Mishell DR. Jr, Guillebaud J, Westhoff C, NelsonAL, Kaunitz AM, Trussell J, Davis AJ. Combinedhormonal contraceptive trials: variable data collectionand bleeding assessment methodologies influencestudy outcomes and physician perception.Contraception (2007) 75; 4-10
  14. Munro M, Critchley H et al. FIGO classificationsystem for causes of AUB innongravid women ofreproductive age. Int J Gynaecol Obstet (2011) 113;3-13
  15. Munro M, Critchley H et al. FIGO classificationsystem for causes of AUB in nongravid women ofreproductive age. Int J Gynaecol Obstet (2011) 113; 3-13
  16. Fraser IS et al. International agreement on terminologiesand definitions used to describe abnormalitiesof menstrual bleeding. Human Reprod (2007) 22; 635-643
  17. Munro M, Critchley H et al. FIGO classificationsystem for causes of AUB in nongravid women ofreproductive age. Int J Gynaecol Obstet (2011) 113; 3-13
  18. Fraser IS et al. International agreement onterminologies and definitions used to describeabnormalities of menstrual bleeding. HumanReprod (2007) 22: 635-643
  19. Graves WP. Some observations on etiology of dysfunctionaluterine bleeding. Am J Obstet Gynecol (1930) 20; 500-518
  20. Fraser IS. The dysfunctional uterus dysmenorrhoea and dysfunctional uterine bleeding.In: Shearman RP, ed. Textbook of clinicalreproductive endocrinology. Edinburgh ChurchillLivingstone (1985) 578-598
  21. Crosignani PG, Rubin B. Dysfunctional uterinebleeding. Human Reprod (1990) 5; 637-638
  22. Ahrendt HJ, Egarter C. Blutungsstörungen unterreiner Gestagen-Langzeitkontrazeption mitsubdermalen Implantaten. Teil 1 und Teil 2.Frauenarzt (2011) 57; 376-382; 493-501
  23. Stenchever MA, Ling FW. Comprehensive Gynecology.4th ed. St Louis, Mo: Mosby (2001)
  24. Vincent AJ, Salamonsen LA: MMP, leucocytes andsteroid-associated uterine bleeding. Hum Reprod15 (2000) 135-144
  25. Krettek JE, Arkin SI, Chaisilwattana P, Monif GR.Chlamydia trachomatis in patients who used oralcontraceptives and had intermenstrualspotting. Obstet Gynecol (1993) 81;728-731
  26. Wallach M, Grimes DA. Modern Oral Contraception. Updates from the Contraceptive Report. Totowa NJ: Emron (2000)
  27. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL.Interaction of St. John’s Wort with oral contraceptives. Effects on the pharmacokinectics of norethindroneand ethinyl estradiol, ovarian activity andbreakthrough bleeding. Contraception (2005) 71;402- 408
  28. Baron JA, Greenberg ER. Cigarette smoking andestrogen related disease in women. In: Smokingand Reproductive Health, ed. Rosenberg MJ.Boston: PSG (1987) 149-160
  29. Jusko WJ. Influence of cigarette smoking on drugmetabolism in man. Drug Met Rev (1979) 9; 221-236
  30. Basu J, Mikhail MS, Palan PR, Thysen B, Bloch E,Romney SL. Endogenous estradiol and progesteroneconcentrations in smokers on oral contraceptives.Gynecol Obstet Invest (1992) 33;224-227
  31. Darney PD. OC practice guidelines: minimizingside effects. Int J Fertil Womens Med (1997) 42 (suppl 1):158-169
  32. Gallinat A, Schmidt T. Operative Behandlungsverfahrenfür dysfunktionelle uterine Blutungen. Ein Kosten-Nutzen-Vergleich. Frauenarzt (2009) 146; 146-149
  33. Day Baird D, Dunson DB, Hill MC, Cousins D,Schectman JM. High cumulative incidence ofuterine leiomyoma in black and white women. Ultrasound evidence. Am J Obstet Gynecol (2003) 188;100-7
  34. Walker CL, Stewart EA. Uterine fibroids: the elephantin the room. Science (2005) 308;1589-92
  35. Day Baird D, Dunson DB, Hill MC, Cousins D,Schectman JM. High cumulative incidence of uterineleiomyoma in black and white women: ultrasoundevidence. Am J Obstet Gynecol (2003)188;100-7
  36. Laughlin SK, Baird DD, Savitz DA, Herring AH,Hartmann KE. Prevalence of uterine leiomyomasin the first trimester of pregnancy. An ultrasoundscreeningstudy. Obstet Gynecol (2009) 113;630-5
  37. Mäkinen Netta, Miika Mehine, Jaana Tolvanen,Eevi Kaasinen, Yilong Li, Heli J. Lehtonen, Gentile M, Jian Yan, Enge M, Taipale M,Aavikko M, Katainen R,Virolainen E,Böhling T, Koski TA, Launonen V,Sjöberg J, Taipale J, Vahteristo P,Lauri A. Aaltonen MED12. The mediator complex subunit 12 gene is mutated at high frequency in uterine leiomyomas. Science (2011) 10;252-255
  38. Yu L, Moore AB, Dixon D. Receptor tyrosine kinasesand their hormonal regulation in uterine leiomyoma.Semin Reprod Med. (2010) 5; 28(3):250-9
  39. Ferenczy A. Pathophysiology of adenomyosis.Hum Reprod Update (1998) 4; 312e322
  40. McCausland AM: Hysteroscopic myometrial biopsy. Its use in diagnosing adenomyosis and itsclinical application. Am J Obstet Gynecol (1992) 166;1619-26
  41. McElin TW, Bird CC. Adenomyosis of the uterus.Obstet Gynecol Annu (1974) 3;425
  42. Hunter WC, Smith LL, Reiner WC. Uterine adenomyosis.Incidence, Symtoms and pathology in1856 hysterectomies. Am J Obstet Gynecol (1947) 53;663-668
  43. Seidman JD, Kjerulff KH. Pathologic findings fromthe Maryland Women’s Health study. Practice patternsin the diagnosis of adenomyosis Int. J.Gynecol. Pathol. (1996) 15;217-221
  44. Parker JD, Leondires M, Sinaii N, Premkumar A,Nieman LK, Stratton P.Persistence of dysmenorrheaand nonmenstrual pain after optimal endometriosissurgery may indicate adenomyosis. FertilSteril (2006) 86(3);711
  45. Templeman C, Marshall SF, Ursin G, Horn-RossPL, Clarke CA, Allen M, Deapen D, Ziogas A,Reynolds P, Cress R, Anton-Culver H, West D,Ross RK, Bernstein L. Adenomyosis and endometriosisin the California Teachers Study. Fertil Steril (2008) 90(2);415
  46. Parazzini F, Vercellini P, Panazza S et al. Riskfactors for adenomyosis. Hum Reprod (1997) 12;1275e-1279
  47. Bakour SH, Gupta JK, Khan KS. Risk factors associatedwith endometrial polyps in abnormal uterinebleeding. Int J Gynaecol Obstet. (2002) 2; 76(2):165-8
  48. Aghajanova L, Velarde MC, Giudice LC. Alteredgene expression profiling in endometrium. Evidencefor progesterone resistance. Semin ReprodMed. (2010) 1;28(1):51-8
  49. Whiteman MK, Zapata LB, Tepper NK,Marchbanks PA, Curtis KM. Use of contraceptivemethods among women with endometrial hyperplasia. A systematic review. Contraception (2010) 7;82(1):56-63
  50. Cushing KL, Weiss NS, Voigt LF, McKnight B,Beresford SA. Risk of endometrial cancer inrelation to use of low-dose, unopposed estrogens.Obstet Gynecol (1998) 91(1):35-9
  51. Shapiro, S., Coleman EA, Broeders M, Codd M, deKoning H, Fracheboud J et al. Breast cancerscreening programmes in 22 countries. Currentpolicies, administration and guidelines.International Breast Cancer Screening Network(IBSN) and the European Network of Pilot Projectsfor Breast. Cancer Screening. Int J Epidemiol (1998) 27(5);735-42
  52. Persson I, Weiderpass E, Bergkvist L, BergstromR, Schairer C. Risks of breast and endome- trialcancer after estrogen and estrogen-progestinreplacement. Cancer Causes Control (1999) 10(4);253-60
  53. Marrett LD, Meigs W, Flannery JT. Trends in the incidenceof cancer of the corpus uteri in Connecticut (1964-1979). In relation to consumption of exogenousestrogens. Am J Epidemiol (1982)116:57-67
  54. Greenwald P, Caputo TA, Wolfgang PE. Endometrialcancer after menopausal use of estrogens. ObstetGynecol (1977)50:239-43
  55. Weiss NS, Szekely DR, Austin DF. Increasing incidenceof endometrial cancer in the United States.N Engl J Med (1976) 294:1259-62
  56. Quint BC. Changing patterns in endometrial adenocarcinoma. A study of 291 consecutive cases at alarge private hospital 1960-1973. Am J ObstetGynecol (1975) 122:498-501
  57. Weiss Noel S., Tom A. Sayvetz. Incidence ofEndometrial Cancer in Relation to the Use of OralContraceptives, N Engl J Med (1980) 302:551-554
  58. Mueck AO, Seeger H, Rabe R. Hormonalcontraception and risk of endometrial cancer: A systematic review, Endocrine-Related Cancer (2010) 17 (4);R263-271
  59. Balen A. Polycystic orary syndrome and cancer.Human Reproduction Update(2001) 7:522-525
  60. Weiderpass E, Adami HO, Baron JA, MagnussonC, Lindgren A, Persson I. Use of oralcontraceptives and endometrial cancer risk (Sweden).Cancer Causes Control (1999)10(4):277
  61. The Cancer and Steroid Hormone Study of theCenters for Disease Control and the National Instituteof Child Health and Human Development.JAMA (1987) 257(6):796
  62. Parslov M, Lidegaard O, Klintorp S, Pedersen B,Jønsson L, Eriksen PS, Ottesen B. Risk factorsamong young women with endometrial cancer. A danish case-control study. Am J Obstet Gynecol (2000) 182(1 Pt 1):23
  63. Tao MH, Xu WH, Zheng W, Zhang ZF, Gao YT,Ruan ZX, Cheng JR, Gao J,Xiang YB, Shu XO.Oral contraceptive and IUD use and endometrial cancer. A population-based case-control study inShanghai, China. Int J Cancer (2006) 119(9):2142
  64. The Cancer and Steroid Hormone Study of theCenters for Disease Control and the National Instituteof Child Health and Human Development.Combination oral contraceptive use and the risk ofendometrial cancer. JAMA (1987) 257(6):796
  65. Mueck AO, Seeger H, Rabe R. Hormonalcontraception and risk of endometrial cancer. A systematic review. Endocrine-Related Cancer (2010) 17 (4):R263-271
  66. Curtis KM, Marchbanks PA, Peterson HB. Neoplasiawith use of intrauterine devices. Contraception (2007) (6 Suppl):60-9
  67. Abu J, Brown L, Ireland D. Endometrial adenocarcinomafollowing insertion of the levonorgestrel-releasingintrauterine system (mirena) in a 36-yearoldwoman. Int J Gynecol Cancer (2006)16 (3):1445-1447
  68. Flemming R, Sathiyathasan S, Jackson A. Endometrioidadenocarcinoma after insertion of a levonorgestrel releasing intrauterine system. J Minim Invasive Gynecol (2008)15 (6):771-773
  69. Jones K, Georgiou M, Hyatt D, Spencer T, Thomas H. Endometrial denocarcinoma following theinsertion of a Mirena IUCD. Gynecol Oncol (2002) 87 (2):216-218
  70. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, WongAW, Kwan WH, Yuen PM. A randomised controlledtrial of prophylactic levonorgestrel intrauterine systemin tamoxifentreated women. BJOG (2007)114 (12):1510-1515
  71. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrelreleasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric (2008) 11 (3): 252-257
  72. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev (4) CD007245-CD007245: (2009) ISSN: 1469-493X
  73. Haimovich S, Checa MA, Mancebo G, Fuste P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. Menopause (2008) 15 (5):1002-1004
  74. Haoula ZJ, Walker KF, Powell MC. Levonorgestrel intrauterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol (2011) 1872-7654
  75. Kresowik J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol (2008) 111 (2 Pt 2) 547-549
  76. Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand (2010) 89 (11): 1438-1446
  77. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrelreleasing intrauterine system for endometrial hyperplasia: A systematic review and metaanalysis. Am J Obstet Gynecol (2010) 203 (6): 547e1-10
  78. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol (2009) 49 (3): 316-322
  79. Ercan CM, Duru NK, Sakinci M, Alanbay I, Karasahin KE, Baser I. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrelreleasing intrauterine system. Gynecol Endocrinol (2010) 26 (2):125-128
  80. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, Jun HS, Park CT. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol 21 (2) 102-105: (2010) ISSN: 2005-0399.
  81. Lee TS, Se¬ong SJ, Kim JW, Ryu HS, Song ES, Nam BH. Management of endometrial hyperplasia with a levonorgestrel releasing intrauterine system. Single arm, prospective multicenter study. Korean gynecologic oncology group study (KGOG2006). Jpn J Clin Oncol (2011) 41 (6): 817-819
  82. Oerbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification. A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol (2008) 111 (1) 68-73
  83. Qi X, Zhao W, Duan Y, Li Y. Successful pregnancy following insertion of a levonorgestrel releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia. Gynecol Obstet Invest (2008) 65 (4): 266-268
  84. Scarselli G, Bargelli G, Taddei GL, Marchionni M, Peruzzi E, Pieralli A, Mattei A, Buccoliero AM, Fambrini M. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertil Steril (2011) 95 (1): 420-422
  85. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol (2008) 139 (2): 169-175
  86. Vereide AB, Arnes M, Straume B, Maltau JM, Oerbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: A study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol (2003) 91 (3): 526-533
  87. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Long-term follow-up. Maturitas (2007) 57 (2): 210-213
  88. Wildemeersch D. Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol (2003) 188 (5): 1297-1298
  89. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol (2005) 97 (3): 924-927
  90. Fambrini M, Bargelli G, Peruzzi E, Buccoliero AM, Pieralli A, Andersson KL, Scarselli G, Gallorini M, Zolfanelli F, Marchionni M. Levonorgestrel releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report. J Minim Invasive Gynecol (2009) 16 (5): 630-633
  91. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol (2004) 95 (3): 762-764
  92. Kim MK, Yoon BS, Park H, Seong SJ, Chung HH, Kim JW, Kang SB. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer (2011) 21 (4): 673-677
  93. Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol (2011) 22 (3): 643-649
  94. Tanmahasamut P. Wongwananuruk T. Challenging Regimen for Long-Term Conservative Treatment of Endometrial Adenocarcinoma in Young Women: A Case Report and Review of the Literature. Case Rep Oncol (2010) 3 (3): 380-385
  95. Vessey MP. An overview of the benefits and risks of combined oral contraceptives. In: Michal F. Safety Requirements for Contraeptive Steroids. Jephcott Lecture (1989) Cambridge University Press
  96. Inki P, Hurskainen R, Palo P, Ekholm E, Grenman S, Kivelä A, Kujansuu E, Teperi J, Yliskoski M, Paavonen J.  Comparison of ovarian cyst formation in women using the levonorgestrel releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol. (2002) Oct;20(4):381-5
  97. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. (2009)
  98. Collaborative Group on Epidemiological Studies of Ovarian Cancer: Ovarian cancer and oral contraceptives. Collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet (2008) 371:303-314
  99. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 24: 11-25
  100. Waggoner SE. Cervical cancer. Lancet (2003) 361: 2217-25
  101. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, Franceschi S, Beral V. Cervical cancer and use of hormonal contraceptives. A systematic review. Lancet (2003) 361(9364):1159
  102. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives. Collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. Lancet(2007) 370 (9599):1609
  103. Critchley HOD, Kelly RW, Brenner RM et al. The endocrinology of menstruation - a role for the immune system. Clin Endocinol (2001) 55:701-710
  104. Critchley HOD, Brenner RM, Hendersin TA et al. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab (2001) 86:1370-1378
  105. Jabbour HN, Kelly RW, Fraser H et al.: Endocrine regulation of menstruation. Endocrine Reviews (2006) 27:17-46
  106. Borthwick JM, Charnock-Jones DS, Tom BD et al. Dertermination of the transcript profile of the human endometrium. Mol Hum Reprod (2003) 9:19-33
  107. Talbi S, Hamilton AE, Vo KC et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phase and underlying biological processes in normoovulatory women. Endocinology (2006) 147:1097-1121
  108. Baird DT: Overview of advances in hormonal contraception. Br Med Bull (2000) 56:704-716
  109. Slayden OD, Mah K, Brenner RM: A critical oeriod of progesterone withdrawel exists for endometrial MMPs and menstruation in macaques.¬ Biol Reprod (1999) 60: 273
  110. Kelly RW, King AE, Critchley HOD: Cytokine control in human endometrium. Reproduction (2001) 121:3-19
  111. CritchleyHOD, Kelly RW, Baird DT et al.: Regulation of human endometrial function: mechanisms relevant to uterine bleeding. Reproductive Biology and Endocrinology (2006) 4 (Suppl 1):1-9
  112. Coneely OM, Lydon JP: Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids (2000) 65:571-577
  113. Perrot-Applanat M, Deng M, Fernandez H et al.: Immunhistological localisation of estradiol and progesterone receptors in human uterus throughout pregnancy: expression in endometrial blood vessels. J Clin Endocrinol Metab (1994) 78:216-224